Analysts' ratings for Arcturus Therapeutics (NASDAQ:ARCT) over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below offers a condensed view of their recent ...

Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Despite a dip in revenue, Arcturus Therapeutics Holdings Inc (ARCT) focuses on innovation and strategic partnerships to bolster its pipeline and financial position. SAN DIEGO (AP) — Arcturus ...